Q-omics provides the consensus-scored MIR208B profile across patient tissues and cancer cell-line models. MIR208B expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR208B is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, MIR208B RNA expression shows 9,193 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, PRAD, and THYM as cancer lineages where MIR208B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR208B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR208B survival associations across molecular data types. MIR208B RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR208B RNA expression–survival associations across cancer types. High MIR208B expression shows unfavorable associations in STAD, READ, BLCA, PAAD, THCA and COAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify STAD as the clearest survival context for MIR208B RNA expression.
This table summarizes MIR208B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR208B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR208B shows lower tumor expression in PRAD. The PRAD box plot shows higher MIR208B RNA expression in normal versus tumor tissue (log2 FC = −0.085, t-test p = .024).
This table shows molecular features associated with MIR208B in patient tissues and cancer cell lines. In patient samples, MIR208B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
